|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 4800 Deerwood Campus Parkway (DCC 2-2) |
Address2 |
|
| City | Jacksonville |
State | FL |
Zip Code | 32246 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 6382-12
|
||||||||
|
6. House ID# 314000000
|
||||||||
| TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Kelly James |
Date | 4/18/2024 11:01:27 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Affordable Care Act (ACA); ACA Subsidies and Tax Credits; Telehealth Flexibilities; Mental Health Care; Youth Mental Health; Site Neutral Payment Reform; Transparency in Coverage; Surprise Billing; 2025 Proposed NBPP/Individual Market/ACA Exchanges; Rural Healthcare; Prior Authorization; Hospital Consolidation; Health Equity Index Reward Factor; Employer-provided Health Coverage; Cyber Attack
HR 485 (118th Congress), Protecting Health Care for All Patients Act of 2023, by Rep. Cathy McMorris Rodgers (R-WA). Prohibits all federal health care programs, including the Federal Employees Health Benefits Program, and federally funded state health care programs (e.g., Medicaid) from using prices that are based on quality-adjusted life years (i.e., measures that discount the value of a life based on disability) to determine relevant thresholds for coverage, reimbursements, or incentive programs.
HR 2708 (118th Congress), Latonya Reeves Freedom Act of 2023, by Rep. Steve Cohen (D-TN). To prohibit discrimination against individuals with disabilities who need long-term services and supports.
HR 2923 (118th Congress), Living Donor Protection Act of 2023, by Rep. Jerrold Nadler (D-NY). To promote and protect living organ donors from discrimination.
HR 3226 (118th Congress), PREEMIE Reauthorization Act of 2023, by Rep. Anna Eshoo (D-CA). Reauthorizes through FY2028 and otherwise modifies research and education programs for preventing premature births.
HR 3417 (118th Congress), FAIR Act, by Rep. Kevin Hern (R-OK). To ensure fair billing practices for items and services furnished by off-campus outpatient departments of a provider.
HR 3630 (116th Congress), No Surprises Act, by Rep. Frank Pallone (D-NJ). To amend title XXVII of the Public Health Service Act to protect health care consumers from surprise billing practices.
HR 3838 (118th Congress), Preventing Maternal Deaths Reauthorization Act of 2023, by Rep. Michael Burgess (R-TX). To amend title III of the Public Health Service Act to reauthorize Federal support of States in their work to save and sustain the health of mothers during pregnancy, childbirth, and the postpartum period, to eliminate disparities in maternal health outcomes for pregnancy-related and pregnancy-associated deaths, to identify solutions to improve health care quality and health outcomes for mothers.
HR 4531 (118th Congress), Support for Patients and Communities Reauthorization Act, by Rep. Brett Guthrie (R-KY). To reauthorize certain programs that provide for opioid use disorder prevention, recovery, and treatment.
HR 5378 (118th Congress), Lower Costs, More Transparency Act, by Rep. Cathy McMorris Rodgers (R-WA). To promote price transparency in the health care sector.
HR 6412 (118th Congress), Down Syndrome Diagnosis Act, by Rep. Marcus Molinaro (R-NY). To amend title XXVII of the Public Health Service Act to provide certain informational resources related to Down syndrome.
HR 7153 (118th Congress), Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, by Rep. Susan Wild (D-PA). To reauthorize the Dr. Lorna Breen Health Care Provider Protection Act, which established grants and required other activities to improve mental and behavioral health among health care providers.
S 644 (118th Congress), Modernizing Opioid Treatment Access Act, by Sen. Ed Markey (D-MA). To expand the take-home prescribing of methadone through pharmacies.
S 652 (118th Congress), Safe Step Act, by Sen. Lisa Murkowski (R-AK). To amend the Employee Retirement Income Security Act of 1974 to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol.
S 1001 (118th Congress), Telehealth Expansion Act of 2023, by Sen. Steve Daines (R-MT). To amend the Internal Revenue Code of 1986 to permanently extend the exemption for telehealth services from certain high deductible health plan rules.
S 1451 (118th Congress), Healthy Competition for Better Care Act, by Sen. Mike Braun (R-IN). To ban anticompetitive terms in facility and insurance contracts that limit access to higher quality, lower cost care.
S 1606 (118th Congress), Black Maternal Health Momnibus Act, by Sen. Cory Booker (D-NJ). To end preventable maternal mortality, severe maternal morbidity, and maternal health disparities in the United States.
S 1869 (118th Congress), SITE Act, by Sen. Mike Braun (D-HI). To amend title XVIII of the Social Security Act and title XXVII of the Public Health Service Act to ensure fair billing practice for items and services furnished by off-campus hospital locations, to amend such title XVIII to provide for payments for graduate nursing education costs.
S 2016 (118th Congress), CONNECT for Health Act of 2023, by Sen. Brian Schatz (D-HI). To amend title XVIII of the Social Security Act to expand access to telehealth services.
S 3430 (118th Congress), Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023, by Sen. Ron Wyden (D-OR). To amend titles XVIII and XIX of the Social Security Act to expand the mental health care workforce and services, reduce prescription drug costs, and extend certain expiring provisions under Medicare and Medicaid.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), White House Office, Executive Office of the President (EOP), Labor - Dept of (DOL)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
Giles |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicaid Redeterminations and Renewals; Medicare Advantage; 340B Program
HR 2880 (118th Congress), Protecting Patients Against PBM Abuses Act, by Rep. Earl Carter (R-GA). To amend title XVIII of the Social Security Act to establish certain requirements for pharmacy benefit managers under Part D of the Medicare program.
HR 5380 (118th Congress), by Rep. John Sarbanes (D-MD). To amend title XVIII of the Social Security Act to increase data transparency for supplemental benefits under Medicare Advantage.
HR 5385 (118th Congress), Medicare PBM Accountability Act, by Rep. Greg Landsman (D-OH). To amend title XVIII of the Social Security Act to establish pharmacy benefit manager reporting requirements with respect to prescription drug plans and MA-PD plans under Medicare Part D.
HR 5386 (118th Congress), Cutting Copays Act, by Rep. Morgan McGarvey (D-KY). To amend title XVIII of the Social Security Act to provide for adjustments to the Medicare Part D cost-sharing reductions for low-income individuals.
HR 5388 (118th Congress), Supporting Innovation for Seniors Act, by Rep. Troy Balderson (R-OH). To amend title XVIII of the Social Security Act to provide coverage of certain technologies and medical devices under the Medicare program.
HR 5663 (118th Congress), ALS Better Care Act, by Rep. Janice Schakowsky (D-IL). To amend title XVIII of the Social Security Act to provide coverage of ALS-related services under the Medicare program for individuals diagnosed with amyotrophic lateral sclerosis.
H.R.5746 (118th Congress), Addressing Whole Health in Medicare Advantage Act, by Rep. Gus Bilirakis (R-FL). To amend title XVIII of the Social Security Act to expand the availability of supplemental benefits to certain Medicare Advantage enrollees.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
Giles |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
COVID Therapeutics; Cell and Gene Therapy; Step Therapy
HR 5372 (118th Congress), Expanding Seniors' Access to Lower Cost Medicines Act of 2023, by Rep. John Joyce (R-PA). To amend Title XVIII of the Social Security Act to facilitate midyear formulary changes for biosimilars.
HR 5376 (117th Congress), Inflation Reduction Act of 2022, by Rep. John Yarmuth (D-KY). Requires the Centers for Medicare & Medicaid Services (CMS) to negotiate the prices of certain prescription drugs under Medicare beginning in 2026.
HR 7312 (118th Congress), EPCS 2.0 Act, by Rep. Ann Kuster (D-NH). To provide requirements for electronic prescribing for controlled substances under group health plans and group and individual health insurance coverage.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
Giles |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |